KV Pharmaceutical Pledges To Improve Finances, But NYSE Demands Action
This article was originally published in The Pink Sheet Daily
Executive Summary
Already plagued by scandal, KV Pharma is subject to NYSE delisting if overdue 2009 annual report is not filed soon.
You may also be interested in...
KV Readies For End-Of-March Makena Launch
Born-again women's specialty pharma renegotiates debt, completes $32 million PIPE, hires 95 new sales reps and sets up a dedicated customer support center for the newly approved drug to prevent preterm birth.
KV Readies For End-Of-March Makena Launch
Born-again women's specialty pharma renegotiates debt, completes $32 million PIPE, hires 95 new sales reps and sets up a dedicated customer support center for the newly approved drug to prevent preterm birth.
Gestiva Approval Unlikely In FY 09; KV Pharmaceutical Admits Credit Fumbles
Firm halts manufacturing and distribution of nearly all products.